HHS & Healthcare Contracts Intelligence — May 02, 2026

$241,937,500 outlayed to date on the $269,952,453 obligation signals strong execution momentum since the 2021-05-25 award, underscoring HHS/ASPR commitment to health preparedness basic research.

As a nonprofit recipient via full and open competition, the $269,952,453 contract offers sustained R&D funding visibility but no direct investment appeal for public equity portfolios.

High pricing risk for GLOBAL HEALTH INVESTMENT CORPORATION under firm fixed price structure in the $269,952,453 BARDA Ventures Other Transaction Agreement with HHS/ASPR.

Long-term health R&D funding potential for GLOBAL HEALTH INVESTMENT CORPORATION via HHS/ASPR/BARDA, with performance extendable to 2041-06-01 beyond current 2031-06-01 end.

HHS awarded $269,952,453 firm fixed price contract to GLOBAL HEALTH INVESTMENT CORPORATION on 2021-05-25 for basic health R&D (PSC AN41), with 90% outlays evidencing sustained funding via BARDA Ventures OTA.

{"entity"=>"GLOBAL HEALTH INVESTMENT CORPORATION", "reason"=>"Progress on remaining ~$28M outlay of $269,952,453 HHS contract obligation amid high firm fixed price execution risk.", "trigger"=>"outlay updates, 2031-06-01 current end date achievement, 2041-06-01 potential extension"}

{"entity"=>"Healthcare R&D sector", "reason"=>"Sustained HHS/ASPR/BARDA funding signals via $270M award and high outlays, despite nonprofit recipient.", "trigger"=>"BARDA Ventures OTA performance milestones"}